The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...